Concepedia

Wentao Feng

WF

Statistics

Publications

54

Citations

4.9K

H-Index

26

Active since

2002

Affiliations

Sichuan University(Current)

Clausthal University of Technology

Sarah Cannon

West China Hospital of Sichuan University

The University of Texas MD Anderson Cancer Center

Wentao Feng is an author at Sichuan University specializing in medicine, oncology, and engineering.

ORCID

Publications per year

2002–2025

54

Publications

54

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

, , +12

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Martine Piccart, Gabriel N. Hortobágyi, Mario Campone et al. · Annals of Oncology · 2014 · 568 citations · Full text

, , +12

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard et al. · Advances in Therapy · 2013 · 520 citations · Full text

, , +17

Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients

Jan Franko, Wentao Feng, Linwah Yip et al. · Journal of Gastrointestinal Surgery · 2009 · 279 citations

, , +14

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

John H. Strickler, Andrea Cercek, Salvatore Siena et al. · The Lancet Oncology · 2023 · 245 citations · Full text

, , +10

1–5 of 54